Beam Therapeutics Inc. — Earnings Quality Grade D
BEAM · Healthcare
Significant concerns
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
Insufficient data
Revenue grew 120.0% but CFFO only 0.6%
Expense Quality
No material inventory
CapEx growth 67.1% vs revenue 120.0%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 4.31. Profits backed by cash
FCF is negative ($-0.4B)
Accruals ratio = 17.9%. Exceeds 10%
Cash $1.2B covers debt $0.2B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -0.4x. Healthy
Other assets -22.2% vs revenue 120.0%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor BEAM continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25